At last, Burkholderia spp. is one of the inclusion criteria - A negative (but published) randomised controlled trial

Journal of Cystic Fibrosis

Volumn 13, Issue 3, 2014, Pages 241-242

  Balfour Lynn, I M ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; BURKHOLDERIA INFECTION; CHRONIC DISEASE; CYSTIC FIBROSIS; EDITORIAL; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); BURKHOLDERIA INFECTIONS; FEMALE; MALE; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; AZTREONAM; BURKHOLDERIA INFECTIONS; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE;

EID: 84897109679     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.01.003     Document Type: Editorial

References (15)

1. Tullis D.E., Burns J.L., Retsch-Bogart G.Z., Bresnik M., Henig N.R., Lewis S.A., et al. Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial. J Cyst Fibros 2014, 13:296-305. [in this issue].
2. House of Commons Committee of Public Accounts Access to clinical trial information and the stockpiling of Tamiflu Available on. [Accessed 3.1.13]. http://www.publications.parliament.uk/pa/cm201314/cmselect/cmpubacc/295/295.pdf.
3. Simes R.J. Publication bias: the case for an international registry of clinical trials. J Clin Oncol 1986, 4:1529-1541.
4. Hopewell S., Loudon K., Clarke M.J., Oxman A.D., Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database Syst Rev 2009, (1). [Art. No.: MR000006]. 10.1002/14651858.MR000006.pub3.
5. Laine C., Horton R., DeAngelis C.D., Drazen J.M., Frizelle F.A., Godlee F., et al. Clinical trial registration: looking back and moving ahead. Lancet 2007, 369:1909-1911.
6. Prayle A.P., Hurley M.N., Smyth A.R. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. BMJ Jan 3 2012, 344:d7373.
7. Stern J.M., Simes R.J. Publication bias: evidence of delayed publication in a cohort study of clinical research projects. BMJ 1997, 315:640-645.
8. Hopewell S., Clarke M.J., Stewart L., Tierney J. Time to publication for results of clinical trials. Cochrane Database Syst Rev 2007, (2). [Art. No.: MR000011]. 10.1002/14651858.MR000011.pub2.
9. Gøtzsche P.C. Deficiencies in proposed new EU regulation of clinical trials. BMJ Dec 20 2012, 345:e8522.
10. Song F., Parekh S., Hooper L., Loke Y.K., Ryder J., Sutton A.J., et al. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess 2010, 14(8).
11. Bourgeois F.T., Murthy S., Mandl K.D. Outcome reporting among drug trials registered in ClinicalTrials.gov. Ann Intern Med 2010, 153:158-166.
12. Cheng K., Preston C., Ashby D., O'Hea U., Smyth R.L. Time to publication as full reports of abstracts of randomized controlled trials in cystic fibrosis. Pediatr Pulmonol 1998, 26:101-105.
13. Hurley M.N., Prayle A.P., Smyth A.R. Delayed publication of clinical trials in cystic fibrosis. J Cyst Fibros 2012, 11:14-17.
14. Horsley A., Jones A.M. Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. Cochrane Database Syst Rev Oct 17 2012, 10. [CD009529]. 10.1002/14651858.CD009529.pub2.
15. Ledson M.J., Gallagher M.J., Robinson M., Cowperthwaite C., Williets T., Hart C.A., et al. A randomized double-blinded placebo-controlled crossover trial of nebulised taurolidine in adult cystic fibrosis patients infected with Burkholderia cepacia. J Aerosol Med 2002, 15:51-57.